Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis

Genomic impact of transient low-dose decitabine treatment on primary AML cells

(2013) J. M. Klco et al.   BLOOD

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

(2013) E H Estey   LEUKEMIA

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

(2012) V. Ghanim et al.   BLOOD

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

(2012) E. Soucie et al.   BLOOD

Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells

(2012) Hsing-Chen Tsai et al.   CANCER CELL

Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis

(2012) Fabiola Traina et al.   PLoS One

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

(2011) Z. Li et al.   BLOOD

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

(2011) Cyril Quivoron et al.   CANCER CELL

Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation

(2011) Kelly Moran-Crusio et al.   CANCER CELL

Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA

(2011) Y.-F. He et al.   SCIENCE

Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine

(2011) S. Ito et al.   SCIENCE

Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit

(2010) A. Gerbaulet et al.   BLOOD

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation

(2010) Maria E. Figueroa et al.   CANCER CELL

Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis

(2010) T. M. Wilson et al.   HAEMATOLOGICA

TET2 mutations in childhood leukemia

(2010) S M C Langemeijer et al.   LEUKEMIA

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

(2009) K. J. Aichberger et al.   BLOOD

Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies

(2009) A. Pardanani et al.   BLOOD

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

(2009) A Tefferi et al.   LEUKEMIA

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

(2009) A Tefferi et al.   LEUKEMIA

Acquired mutations in TET2 are common in myelodysplastic syndromes

(2009) Saskia M C Langemeijer et al.   NATURE GENETICS

Mutation inTET2in Myeloid Cancers

(2009) François Delhommeau et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis

(2008) S. Verstovsek et al.   CLINICAL CANCER RESEARCH

Acute lymphoblastic leukemia and cutaneous mastocytosis in two children

(2008) Caroline Masserot et al.   PEDIATRIC BLOOD & CANCER